Clinical management of cutaneous toxicity of anti-EGFR agents

Marcello Monti, S. Motta

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Cutaneous toxicity is the most evident adverse effect of epidermal growth factor receptor (EGFR) inhibitors because of the specific role played by EGFR in skin biophysiology. Dermatological adverse reactions, mainly folliculocentric, have been widely reported in the literature. However, the mechanism of these reactions is not well defined and their management is still a matter of debate. In this paper keratinocyte differentiation, activation and pathways regulating gene expression are reviewed in order to improve the understanding of adverse skin reactions and obtain success in their management. The authors had the opportunity to treat skin reactions induced by cetuximab in a cohort of patients affected by metastatic colorectal carcinoma. The aims of this clinical approach were to control the signs and symptoms of skin toxicity in order to avoid delay in cancer therapy and to use nondrug agents for the treatment of drug-induced skin reactions.

Original languageEnglish
JournalInternational Journal of Biological Markers
Volume22
Issue number1 SUPPL. 4
Publication statusPublished - Jan 2007

Fingerprint

Epidermal Growth Factor Receptor
Toxicity
Skin
Gene expression
Keratinocytes
Signs and Symptoms
Chemical activation
Colorectal Neoplasms
Gene Expression
Pharmaceutical Preparations
Therapeutics
Neoplasms

Keywords

  • Anti-EGFR skin toxicity
  • Natural products
  • Skin inflammation

ASJC Scopus subject areas

  • Immunology
  • Biochemistry

Cite this

Clinical management of cutaneous toxicity of anti-EGFR agents. / Monti, Marcello; Motta, S.

In: International Journal of Biological Markers, Vol. 22, No. 1 SUPPL. 4, 01.2007.

Research output: Contribution to journalArticle

@article{95f89b4f611c45939b494a7e14f2483e,
title = "Clinical management of cutaneous toxicity of anti-EGFR agents",
abstract = "Cutaneous toxicity is the most evident adverse effect of epidermal growth factor receptor (EGFR) inhibitors because of the specific role played by EGFR in skin biophysiology. Dermatological adverse reactions, mainly folliculocentric, have been widely reported in the literature. However, the mechanism of these reactions is not well defined and their management is still a matter of debate. In this paper keratinocyte differentiation, activation and pathways regulating gene expression are reviewed in order to improve the understanding of adverse skin reactions and obtain success in their management. The authors had the opportunity to treat skin reactions induced by cetuximab in a cohort of patients affected by metastatic colorectal carcinoma. The aims of this clinical approach were to control the signs and symptoms of skin toxicity in order to avoid delay in cancer therapy and to use nondrug agents for the treatment of drug-induced skin reactions.",
keywords = "Anti-EGFR skin toxicity, Natural products, Skin inflammation",
author = "Marcello Monti and S. Motta",
year = "2007",
month = "1",
language = "English",
volume = "22",
journal = "International Journal of Biological Markers",
issn = "0393-6155",
publisher = "Wichtig Publishing Srl",
number = "1 SUPPL. 4",

}

TY - JOUR

T1 - Clinical management of cutaneous toxicity of anti-EGFR agents

AU - Monti, Marcello

AU - Motta, S.

PY - 2007/1

Y1 - 2007/1

N2 - Cutaneous toxicity is the most evident adverse effect of epidermal growth factor receptor (EGFR) inhibitors because of the specific role played by EGFR in skin biophysiology. Dermatological adverse reactions, mainly folliculocentric, have been widely reported in the literature. However, the mechanism of these reactions is not well defined and their management is still a matter of debate. In this paper keratinocyte differentiation, activation and pathways regulating gene expression are reviewed in order to improve the understanding of adverse skin reactions and obtain success in their management. The authors had the opportunity to treat skin reactions induced by cetuximab in a cohort of patients affected by metastatic colorectal carcinoma. The aims of this clinical approach were to control the signs and symptoms of skin toxicity in order to avoid delay in cancer therapy and to use nondrug agents for the treatment of drug-induced skin reactions.

AB - Cutaneous toxicity is the most evident adverse effect of epidermal growth factor receptor (EGFR) inhibitors because of the specific role played by EGFR in skin biophysiology. Dermatological adverse reactions, mainly folliculocentric, have been widely reported in the literature. However, the mechanism of these reactions is not well defined and their management is still a matter of debate. In this paper keratinocyte differentiation, activation and pathways regulating gene expression are reviewed in order to improve the understanding of adverse skin reactions and obtain success in their management. The authors had the opportunity to treat skin reactions induced by cetuximab in a cohort of patients affected by metastatic colorectal carcinoma. The aims of this clinical approach were to control the signs and symptoms of skin toxicity in order to avoid delay in cancer therapy and to use nondrug agents for the treatment of drug-induced skin reactions.

KW - Anti-EGFR skin toxicity

KW - Natural products

KW - Skin inflammation

UR - http://www.scopus.com/inward/record.url?scp=34248338628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248338628&partnerID=8YFLogxK

M3 - Article

C2 - 17520582

AN - SCOPUS:34248338628

VL - 22

JO - International Journal of Biological Markers

JF - International Journal of Biological Markers

SN - 0393-6155

IS - 1 SUPPL. 4

ER -